Clinical Trial Update: Atrasentan in Patients With Proteinuric Glomerular Diseases [Phase 2]

View source ↗

Summary

Phase 2 trial of atrasentan for proteinuric glomerular diseases is active but not recruiting, including IgA nephropathy, Focal segmental glomerulosclerosis, Alp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alport Syndrome
• Diabetic Nephropathy
• Focal Segmental Glomerulosclerosis
• Iga Nephropathy

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING